The European Pharmaceutical Contract Manufacturing market is anticipated to grow at a modest CAGR of around 6.1% during the forecast period (2021-2027). The European pharmaceutical contract manufacturing market has witnessed impressive growth over the past few decades. Pharmaceutical contract manufacturing company provides cost-effective drug development and manufacturing solutions to pharmaceutical and biotech companies. In the wake of the COVID-19 pandemic, the demand for generic medicines has increased. Many pharmaceutical organizations in European countries have hired CDMO to develop more medicines and pharmaceutical products during the COVID-19 pandemic, this led to market growth.
Browse the full report description of "European Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Manufacturing Process Type (Sterile Manufacturing, and Non-Sterile Manufacturing) By Product Type (OTC, API, Finished Dosage Formulation, and Others) By Route of Administration (Oral, Inhaled, Parenteral, and Others) By Service (R&D, Manufacturing, and Non-Clinical) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/european-pharmaceutical-contract-manufacturing-market
The availability of skilled labor, improved infrastructure, and government policies, and increasing uptake of biologics and generics are the major factors driving the growth of the European pharmaceutical contract manufacturing market during the forecast period. Pharmaceutical companies contract with CDMO to increase their capabilities of commercial production and to increase the supply of numbers of the vaccine. Besides, the rising mergers and acquisitions among market players to expand their product offerings and manufacturing units is the factor that also propelling the market growth in the European region.
For instance, in February 2020, Catalent Pharma Solutions acquired MaSTherCell Global, a contract development manufacturing organization (CDMO) subsidiary of Orgenesis to further expand their product offerings for point-of-care cell therapy and the development of advanced therapy medicinal products. Moreover, in May 2019, EVER Pharma Holding Ges.m.b.H completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals to extend its commercial presence in Europe. With this acquisition, EVER Pharma extended its portfolio in Germany.
Market Coverage
o By Manufacturing Process Type
o By Product Type
o By Route of Administration
o By Service
o Europe
? UK
? Germany
? Italy
? Spain
? France
? RoE
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
European Pharmaceutical Contract Manufacturing Market Report by Segment
By Manufacturing Process Type
By Product Type
o Solid Dose
o Liquid Dose
o Injectable Dose
By Route of Administration
By Service
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-pharmaceutical-contract-manufacturing-market